Clinical Kidney Journal最新文献

{"title":"Clinicopathological features and predictors of anti-GBM disease combined with membranous nephropathy.","authors":"Yuanyuan Wu, Lijie Zhang, Zhanzheng Zhao","doi":"10.1093/ckj/sfaf014","DOIUrl":"10.1093/ckj/sfaf014","url":null,"abstract":"<p><strong>Background: </strong>Anti-glomerular basement membrane (anti-GBM) disease is a rare and life-threatening form of small vessel vasculitis that primarily affects the kidneys and lungs. In rare cases, it occurs with membranous nephropathy (MN). This study aimed to investigate the clinical manifestations, pathological features, prognosis and predictors of anti-GBM disease with MN.</p><p><strong>Methods: </strong>We enrolled 24 patients with combined anti-GBM disease and MN, and 69 patients with classic anti-GBM disease (without MN). We compared the clinical and pathological differences, as well as the prognoses between the two groups and attempted to identify predictors of anti-GBM disease combined with MN.</p><p><strong>Results: </strong>A greater proportion of patients with combined disease were male, had a history of smoking, and had nephrotic syndrome (NS). Compared with patients with classic anti-GBM disease, those with anti-GBM disease with MN presented improved renal function, higher hemoglobin and serum C3 levels, and significantly improved renal outcomes (<i>P </i>< .05). In 16 out of 24 double-positive patients, a lower proportion of glomerular crescents and a higher rate of immunoglobulin G4 positivity were observed compared with only 20 of the 69 patients with classic anti-GBM disease confirmed by renal biopsy (<i>P </i>< .05). Furthermore, smoking status, hemoglobin levels and low-density lipoprotein levels were identified as factors associated with the development of anti-GBM combined with MN, potentially serving as predictors.</p><p><strong>Conclusions: </strong>This study provides insights into the distinct clinical and pathological characteristics of anti-GBM disease with MN. The identification of predictors may contribute to the early recognition and management of these patients.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf014"},"PeriodicalIF":3.9,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy.","authors":"Emanuel Lohrmann, Thomas Jaeger, Kene Enekebe, Zhen Zhang, Timothy Wilt, Michele Riggen, Annette Stemhagen, Indu Nair, Sasikiran Nunna, Ancilla W Fernandes, Hema Gandhi, Olga Sergeyeva, Vinu George","doi":"10.1093/ckj/sfaf062","DOIUrl":"10.1093/ckj/sfaf062","url":null,"abstract":"<p><strong>Background: </strong>Approval of tolvaptan in the USA for the treatment of autosomal dominant polycystic kidney disease (ADPKD) was contingent on implementation of a Risk Evaluation and Mitigation Strategy (REMS) that includes monitoring for drug-induced liver injury (DILI). Liver safety data from the REMS were published previously for the period from program start (May 2018) to February 2021. To further characterize the post-marketing liver safety of tolvaptan, we provide a REMS update.</p><p><strong>Methods: </strong>We analyzed prospective pharmacovigilance data on ADPKD patients who initiated tolvaptan in the post-marketing setting. The data capture period was May 2018 to February 2023.</p><p><strong>Results: </strong>Among 10 879 tolvaptan-treated patients, exposure was >12 months for 45% and >18 months for 35%. Since the 3-year analysis, in which 60/6711 (0.9%) patients were reported with possible severe DILI, the frequency has remained consistent for 5 years [i.e. 82/10 879 (0.8%)]. Incidence of possible severe DILI in the REMS at 5 years was 0.52 events per 100 patient years. Confirmation of possible severe DILI events as serious and potentially fatal was made for 4/82 events, with no new cases confirmed since the 3-year reporting period. No fatalities or liver transplants attributable to tolvaptan-related DILI have been reported in the REMS.</p><p><strong>Conclusions: </strong>Five years of data support adherence to the per-label tolvaptan liver function monitoring schedule to promptly detect and manage liver toxicity. Conclusions are limited by data availability at the time of analysis cutoff, with the possibility that additional cases of possible severe DILI and/or serious and potentially fatal events may be identified.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf062"},"PeriodicalIF":3.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal relationships between immune cell phenotypes and primary glomerular diseases: genetic evidence from bidirectional Mendelian randomization study.","authors":"Wenhao Tang, Qiu Li, Xueying Yang, Haiping Yang","doi":"10.1093/ckj/sfaf057","DOIUrl":"10.1093/ckj/sfaf057","url":null,"abstract":"<p><strong>Background: </strong>Primary glomerular diseases (PGDs), including nephrotic syndrome (NS), membranous nephropathy (MN), and IgA nephropathy (IgAN), are complex renal conditions influenced by immune system dysregulation. Although associations between immune cell phenotypes and PGDs have been observed, the precise causal relationships have not been fully elucidated.</p><p><strong>Methods: </strong>Utilizing genetic association data from genome-wide association studies (GWASs), we investigated 731 immunophenotypes in relation to PGDs. A bidirectional two-sample Mendelian randomization (MR) approach, primarily employing inverse variance weighting (IVW), was conducted to establish causality. MR-Egger, weighted median, simple mode, and weighted mode were used as complementary methods to reinforce the robustness and validity of the results. Sensitivity analyses further validated the sensitivity and stability of our results.</p><p><strong>Results: </strong>We identified 38 immunophenotypes suggestively related to IgAN, with 20 as risk factors and 18 as protective effects. Six immunophenotypes remained significant after Bonferroni correction: The percentage of CD25hi among T cells; the percentage of CD25hi CD45RA^- CD4 not T regulatory (Treg) among T cells; the percentage of CD25hi CD45RA^- CD4 not Treg within the CD4⁺ T cell population; CX3CR1 expression on monocytes; CD40 expression on monocytes; and CD64 expression on CD14⁺ CD16^- monocytes. In the validation analysis of IgAN, CD3 expression on effector memory CD4⁺ T cells further confirmed the predisposing risk role of effector memory T cells in the development of IgAN. Additionally, the MR analysis demonstrated suggestive associations between 25 immunophenotypes and MN (8 risk factors and 17 protective factors), as well as between 22 immunophenotypes and NS (10 risk factors and 12 protective factors). Last, by intersecting the immunophenotypes showing suggestive associations with PGDs, we identified two common immunophenotypes shared by IgAN and MN, three by IgAN and NS, and one by MN and NS.</p><p><strong>Conclusions: </strong>This genetic-level investigation uncovers causal associations between immunophenotypes and PGDs, providing valuable insights into the immunological underpinnings of PGDs. Our findings suggest potential targets for treatment strategies, thereby facilitating more personalized and effective therapeutic approaches in PGDs management.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf057"},"PeriodicalIF":3.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 60:40 conundrum: are women with CKD discriminated after referral to a nephrology clinic?","authors":"Adele Vautcranne, Lavinia Bianco, Béatrice Mazé, Antioco Fois, Antoine Chatrenet, Maria Rita Moio, Gulia Santagati, Linda Njandjo, Pierre-Yves de Müllenheim, Massimo Torreggiani, Giorgina Barbara Piccoli","doi":"10.1093/ckj/sfaf046","DOIUrl":"10.1093/ckj/sfaf046","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological data show that chronic kidney disease (CKD) is more prevalent among females than males but the prevalence of women in dialysis is lower, as is their representation in nephrology trials. We aimed to test whether sex distribution varies at nephrology referral, inclusion in a trial, or at the starting of dialysis.</p><p><strong>Methods: </strong>We evaluated patients' characteristics at the time of the first consultation in the Unit for the Care of Advanced CKD (UIRAV), at the inclusion in an observational study (PRO-RE-RE-PRO) and at the beginning of dialysis. Patient and renal survival analysis was performed in the pre-dialysis phase and after dialysis start. Reasons for denying participation to the proposed study and causes of death or withdrawal from follow-up and dialysis were likewise examined.</p><p><strong>Results: </strong>During the period 2017-2023, 866 patients were referred to the UIRAV, 59% males and 41% females. Female patients were older, had lower comorbidity and were referred at the same eGFR than males. The same male/female proportion was observed in patients included in the PRO-RE-RE-PRO study and at dialysis start. Survival was significantly higher in females. Overall, distribution across sex remained stable over time.</p><p><strong>Conclusions: </strong>Males and females are referred at similar eGFR levels, which appears to be the main reason for seeking nephrology care. Afterward, the ratio between males and females remains stable, suggesting that if a sex-selection bias exists, it should be sought before the first nephrology referral. However, further studies are needed to ensure that health equity is respected across sexes.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf046"},"PeriodicalIF":3.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases.","authors":"Jeffery C H Chan, Eugene Yu-Hin Chan, Samuel M S Cheng, Daniel Leung, Fanny Tsz-Wai Ho, Pak-Chiu Tong, Wai-Ming Lai, Matthew H L Lee, Stella Chim, Leo C H Tsang, Tsz-Chun Kwan, Yin Celeste Cheuk, Manni Wang, Howard H W Wong, Amos M T Lee, Wing Yan Li, Sau Man Chan, Issan Y S Tam, Jennifer H Y Lam, Kaiyue Zhang, Wenwei Tu, Malik Peiris, Jaime S Rosa Duque, Yu Lung Lau, Alison Lap-Tak Ma","doi":"10.1093/ckj/sfaf052","DOIUrl":"10.1093/ckj/sfaf052","url":null,"abstract":"<p><strong>Background: </strong>Children with chronic kidney disease (CKD) are at risk of severe complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and are recommended to receive vaccine boosters. Although coronavirus disease 2019 (COVID-19) boosters are effective in providing immune responses among healthy children, data on the use of a fourth dose among children with CKD are limited.</p><p><strong>Methods: </strong>We prospectively investigated the immunogenicity and safety of a fourth dose of BNT162b2 in children with CKD. Dosages were 0.1 mL and 0.3 mL for children aged 5-11 years and 11-18 years, respectively. Humoral and cellular immunogenicity was assessed at pre-dose 4, and at 1 and 6 months post-dose 4.</p><p><strong>Results: </strong>Twenty-one children, with a median age of 14.0 years, were included for evaluation. A fourth dose of BNT162b2 elicited significant increases in humoral spike receptor-binding domain immunoglobulin G levels and T-cell responses. Antibody responses were significantly lower among kidney transplant recipients or children receiving calcineurin inhibitors than other CKD children at 1 month post-dose 4. Breakthrough COVID-19 occurred in three children after the fourth dose, and one was hospitalized. One child developed mild gross hematuria 1 day after the fourth dose, which spontaneously resolved. The overall safety profile was acceptable.</p><p><strong>Conclusions: </strong>A fourth dose of BNT162b2 was immunogenic and safe in children with CKD.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf052"},"PeriodicalIF":3.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney outcomes of malignant hypertension-associated thrombotic microangiopathy in patients with and without IgA nephropathy: a propensity score-matched analysis.","authors":"Wenchuan Li, Rong Lian, Yuejiao Li, Xingji Lian, Zefang Dai, Zhong Zhong, Wanxin Shi, Yiqin Wang, Wei Chen, Jianbo Li, Feng He","doi":"10.1093/ckj/sfaf017","DOIUrl":"10.1093/ckj/sfaf017","url":null,"abstract":"<p><strong>Background: </strong>IgA nephropathy (IgAN) can cause hypertension, and severe hypertension can exacerbate the progression of IgAN. However, the long-term kidney outcome of malignant hypertension (mHTN)-associated thrombotic microangiopathy (TMA) with IgAN is not well defined.</p><p><strong>Methods: </strong>A total of 292 individuals with mHTN-associated TMA confirmed by kidney biopsy were included. Propensity score matching (PSM) analysis was performed to adjust for clinical characteristics in the comparison between cases with and without IgAN. Cox regression analysis was utilized to identify risk factors associated with long-term kidney outcome.</p><p><strong>Results: </strong>A total of 86 mHTN-associated TMA with IgAN patients were compared with 206 mHTN-associated TMA with non-IgAN patients. After PSM, 61 pairs of patients with mHTN-associated TMA were matched. The mHTN-associated TMA with IgAN patients exhibited significantly lower serum albumin, higher 24-hour proteinuria, and a higher ratio of global sclerosis than those with non-IgAN. mHTN-associated TMA with IgAN was independently associated with impaired kidney function recovery [hazard ratio (HR), 0.48; 95% confidence interval (CI), 0.24-0.96, <i>P</i> = .038] compared with non-IgAN. This association remained significant after PSM (HR, 0.41; 95% CI, 0.17-0.99, <i>P</i> = .047). In addition, mHTN-associated TMA with IgAN was independently associated with kidney replacement therapy (KRT) compared with non-IgAN (HR, 2.31; 95% CI, 1.38-3.88; <i>P</i> = .002). This difference remained significant after PSM comparison (HR, 2.38; 95%CI, 1.14-4.99; <i>P</i> = .021). In addition, mHTN-associated TMA with IgAN patients had a higher incidence of receiving KRT and a lower incidence of kidney function recovery with a 25% reduction in creatinine levels than in non-IgAN patients, regardless of intensive blood pressure control.</p><p><strong>Conclusions: </strong>The long-term kidney outcomes for mHTN-associated TMA patients with concomitant IgAN are significantly poorer than that of patients with non-IgAN. Monitoring kidney pathological characteristics will aid management and risk assessment at an early stage.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf017"},"PeriodicalIF":3.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of rituximab and plasma exchange in treatment and prophylaxis of recurrent FSGS.","authors":"Sophie Gharaei, Julia Gharaei, Omar Ragy, Durga A K Kanigicherla","doi":"10.1093/ckj/sfaf058","DOIUrl":"10.1093/ckj/sfaf058","url":null,"abstract":"<p><strong>Background: </strong>Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome and renal failure, requiring transplantation. However, FSGS can often recur after transplantation resulting in graft failure. The most used therapeutic intervention for rFSGS is plasma exchange (PE), with variable success. Recently, rituximab has found increasing use in both treatment and prevention of recurrent FSGS.</p><p><strong>Methods: </strong>We undertook a systematic review of therapeutic ± preventative plasma exchange, rituximab or a combination of both for recurrent FSGS. Studies published between 2017 and 2024 were included, to reflect the most contemporary clinical practice.</p><p><strong>Results: </strong>Twenty-seven studies with a total of 475 patients received treatment for recurrence post-transplantation and/or for prevention of recurrent FSGS. Of 221 patients who received plasma exchange on its own as therapy, 156 (71%) achieved either complete or partial remission. Rituximab alone was used in only four patients (75% remission rate), while 67% achieved remission with a combination of both. One hundred and forty-two patients received pre/peri-transplantation treatment to prevent recurrence in the graft. Fifty-one patients (36%) experienced recurrence despite prophylaxis. Recurrence rates were 35% with plasma exchange alone and 38% with rituximab alone<i>.</i></p><p><strong>Conclusion: </strong>We conclude that rituximab did not add significant benefit to plasma exchange when used as initial therapeutic intervention in post-transplant recurrent FSGS. The modest benefit of prophylactic therapies highlights the need for risk stratification to identify patients most likely to benefit from such interventions. Larger prospective studies with standardized approaches to treatment are essential in improving outcomes in rFSGS.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf058"},"PeriodicalIF":3.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of gastric acid suppressants on peritonitis risk in peritoneal dialysis patients: a systematic review and meta-analysis.","authors":"Ching-Chung Hsiao, Chieh-Li Yen, Shu-Chun Huang, Cheng-Yi Chen, Ya-Chung Tian, Yung-Chang Chen, Wen-Yu Ho, Jia-Jin Chen","doi":"10.1093/ckj/sfaf054","DOIUrl":"10.1093/ckj/sfaf054","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf054"},"PeriodicalIF":3.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD163 detection in immune check-point inhibitors-related acute interstitial nephritis.","authors":"Thomas Perier, Yves Renaudineau, Juliette Pellegrini, Magali Colombat, Angie Arango Ramirez, Pierre Guy, Thibaut Jamme, Nathalie Van Acker, Clément Koundé, David Ribes, Antoine Huart, Audrey Casemayou, Julie Belliere","doi":"10.1093/ckj/sfaf009","DOIUrl":"10.1093/ckj/sfaf009","url":null,"abstract":"<p><strong>Background: </strong>Acute interstitial nephritis (AIN) is the most common renal immune-related adverse event after immune check-point inhibitors (ICI). We hypothesized that alternatively activated macrophages (CD163-M) could be involved in ICI-AIN and wished to evaluate the use of their soluble urinary form (us)CD163 as a non-invasive diagnostic marker.</p><p><strong>Methods: </strong>CD163-M infiltrates were evaluated by both immune-histochemistry and multiplex immunofluorescence and imaging. usCD163 was detected with ELLA technology and evaluated together with urinary creatinine to be expressed as a ratio to creatinuria in ng/mmol. Clinical data were collected to perform correlations with renal function assessed by estimated glomerular filtration rate (eGFR).</p><p><strong>Results: </strong>A retrospective cohort of 63 ICI-exposed patients with tubular acute kidney injury profile requiring a biopsy were selected. AIN patients (<i>n</i> = 44) were compared to acute tubular necrosis (ATN) patients (<i>n</i> = 19). CD163-M staining was detectable in all ICI-AIN patients, which was significantly higher than in ATN patients (18.4% vs 3.6% of area, <i>P</i> <i> </i>= .005). CD163-M staining was restricted to the interstitial compartment. CD163-M infiltrate inversely correlated with initial eGFR (<i>r</i> = -0.6, <i>P</i> <i> </i>= .003), and was positively correlated with delta eGFR, reflecting a renal improvement outcome (<i>r</i> = 0.48; <i>P</i> <i> </i>= .02). usCD163 was well detected in urines of patients, but did not allow us to distinguish ATN from AIN patients at diagnosis. No correlation was observed, neither between usCD163 and CD163-M staining nor with renal response after 3 months of glucocorticoid tapering.</p><p><strong>Conclusion: </strong>CD163-M are detected in ICI-AIN and correlate both with severity at diagnosis and better prognosis at 3 months. CD163-M may help us to distinguish AIN from ATN but, it does not allow us to assess ICI imputability. Although detected in urine, usCD163 is clearly not a surrogate biomarker for AIN diagnosis.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf009"},"PeriodicalIF":3.9,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Mortality associated with the COVID-19 pandemic in the Swiss dialysis population beyond SARS-CoV-2 infection.","authors":"","doi":"10.1093/ckj/sfaf042","DOIUrl":"https://doi.org/10.1093/ckj/sfaf042","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/ckj/sfae322.].</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfaf042"},"PeriodicalIF":3.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}